Yichang Technology: the net profit in 2021 was 74.3696 million yuan, with a year-on-year increase of 12.95%
Yichang technology released its annual report for 2021, realizing an operating revenue of 3.744 billion yuan, a year-on-year increase of 22.24%; The net profit attributable to the parent company was 74.3696 million yuan, a year-on-year increase of 12.95%; The basic earnings per share is 0.19 yuan.
This text is a result of machine translation.
Related companies：
Briefing Jun 20, 2022 04:54 PM
· Technology
The official results of the French parliamentary elections were announced, and the ruling party coalition held a relatively large number of seats
In-depth
Healthcare
Big Pharma CCHT’s Domination Unlikely to Fade Soon Despite Official Bulk Buying
The producer of long-acting growth hormone acupunctures, vaccines and other drugs, looks set to offset the effects of so-called “centralized procurement” on its product prices with more aggressive expansion into private hospitals. So far, its monopoly appears unshakable, but with more competitors upping the stakes, how long will it last?
Feb 21, 2022 02:30 PM
May 02, 2022 07:50 PM
Apr 25, 2022 01:02 PM
Research
Consumer StaplesChina’s Food and Beverage Industry in Search of Methods to Shrink its Carbon Footprints
Apr 19, 2022 11:38 PM
Apr 18, 2022 09:14 PM
In-depth
Technology
Successful Multinational Corporations in China Series: Qualcomm China
Since China's reform and opening-up, many multinational corporations and groups have achieved success in China. They have not only been successful in their fields, but some also benefitted from wise M&A moves or investments. To answer these questions EqualOcean launches its Successful Multinational Corporations in China and analyzes the critical points of investing in China for investors and people interested in such a topic.
Jun 25, 2022 02:02 PM
In-depth
Healthcare
BeiGene: a Vast Opportunity Lies Ahead – But We Remain Cautious
BeiGene, a leader in China's novel pharmaceutical industry, recently received approval in Kuwait, Bahrain, and Qatar for its medication BRUKINSA (zanubrutinib). Previous contracts with major biopharma have produced substantial licensing income, but they did not lessen BeiGene's financial burden.
Jun 24, 2022 12:13 PM
Briefing Jan 21, 2022 12:19 PM
· Technology
Changchun hi tech: nine directors, supervisors and senior management personnel increased their holdings of 84700 shares in the company
Briefing Jan 20, 2022 02:49 PM
· Technology
Consumer electronics stocks continued to decline
See more
Read next
In-depth
Technology
Successful Multinational Corporations in China Series: Qualcomm China
Jun 25, 2022 02:02 PM
EqualOcean is an information service provider and investment research company that aims to become a global platform for industrial innovation. Founded in February 2014 and headquartered in Beijing, with a client network covering over 50 countries, the firm provides comprehensive professional services, including industry research, investment analysis, innovation consulting, data products, corporate branding and international strategy.